CHOLANGIOCARCINOMA

This study tested a new drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block FGFR2, which can help slow or shrink tumors. The goal was to find the best dose and see how well it…

This early-phase study tested a new drug called cabotamig in 33 adults with advanced gastrointestinal cancers (like colon, stomach, liver, or pancreatic cancer) that had stopped responding to standard treatments. The drug works by attaching to a marker on cancer cells and helping…

This study tested whether a Medtronic pump and Codman catheter could safely deliver chemotherapy directly to the liver in 35 people with colorectal cancer or bile duct cancer that spread to the liver. The goal was to see if this device combination is a safe alternative to an olde…

This study tested an oral drug called infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The goal was to see if the drug could shrink or control the cancer by blocking overactive FGFR proteins. While not a cure, the treatmen…

This early-phase study tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 gene mutation. The goal was to find the safest dose and see how the drug works in the body.…

This study tested a combination of three treatments—chemotherapy directly into the liver, a targeted drug, and an immunotherapy—for people with advanced bile duct cancer that cannot be removed by surgery. The goal was to see if the combination is safe and shrinks tumors. 25 parti…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease (small amounts of cancer left after standard treatment). The goal was to see if t…

This study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion) and has stopped responding to standard chemotherapy. The main goal was to see if the drug could shrink tumors. The drug targets the ca…

This study looked at 200 people with suspected hilar cholangiocarcinoma, a cancer at the liver's bile duct junction. Researchers compared two biopsy methods—one using an endoscope through the mouth (EUS-FNA/B) and another using a scope through the bile duct (ERCP with or without …

This study tested a new imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if this PET scan could better detect cancer cells compared to standard methods. Resear…

This study looked at whether a blood test can tell if bile duct cancer has spread to nearby lymph nodes before surgery. Researchers tested blood samples from 230 patients with intrahepatic cholangiocarcinoma. The goal is to help doctors choose the best treatment without needing i…

This study tested a new method called the mass response biomarker to see if it can predict how well a cancer patient will respond to specific treatments. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or tissue biopsies. The goal was to …

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…

This study looked at how often the EchoTip AcuCore biopsy needle successfully gets a tissue sample during endoscopic ultrasound procedures. It included 183 adults with various conditions like cancer or pancreatitis. The goal was to gather real-world information on the device's pe…